Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach
Checkpoint inhibitors (ICIs) have demonstrated substantial efficacy in the treatment of numerous solid tumors, including head and neck cancer. Their inclusion in the therapeutic paradigm in metastatic lines of treatment has certainly improved the outcomes of these patients. Starting from this assump...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/10/2337 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850205196808880128 |
|---|---|
| author | Alessia Zotta Maria Luisa Marciano Francesco Sabbatino Alessandro Ottaiano Marco Cascella Monica Pontone Massimo Montano Ester Calogero Francesco Longo Morena Fasano Teresa Troiani Fortunato Ciardiello Fabiana Raffaella Rampetta Giovanni Salzano Giovanni Dell’Aversana Orabona Luigi Califano Franco Ionna Francesco Perri |
| author_facet | Alessia Zotta Maria Luisa Marciano Francesco Sabbatino Alessandro Ottaiano Marco Cascella Monica Pontone Massimo Montano Ester Calogero Francesco Longo Morena Fasano Teresa Troiani Fortunato Ciardiello Fabiana Raffaella Rampetta Giovanni Salzano Giovanni Dell’Aversana Orabona Luigi Califano Franco Ionna Francesco Perri |
| author_sort | Alessia Zotta |
| collection | DOAJ |
| description | Checkpoint inhibitors (ICIs) have demonstrated substantial efficacy in the treatment of numerous solid tumors, including head and neck cancer. Their inclusion in the therapeutic paradigm in metastatic lines of treatment has certainly improved the outcomes of these patients. Starting from this assumption, numerous studies have been conducted on ICIs in other earlier disease settings, including studies conducted in patients in neoadjuvant settings. However, how many and which studies are truly significant? Can they lay concrete foundations for further future studies and therefore allow us to continue to have this interesting future perspective? Through a review of the existing literature, coupled with insights gleaned from clinical practice and from the main recently published studies, we aim to examine the therapeutic potential of ICIs in patients affected by head and neck cancer in a neoadjuvant treatment setting and encourage researchers to set up successful future clinical trials. |
| format | Article |
| id | doaj-art-1fdce2e9e6d04b4c9f9c62fcc5e2ab63 |
| institution | OA Journals |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-1fdce2e9e6d04b4c9f9c62fcc5e2ab632025-08-20T02:11:09ZengMDPI AGBiomedicines2227-90592024-10-011210233710.3390/biomedicines12102337Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment ApproachAlessia Zotta0Maria Luisa Marciano1Francesco Sabbatino2Alessandro Ottaiano3Marco Cascella4Monica Pontone5Massimo Montano6Ester Calogero7Francesco Longo8Morena Fasano9Teresa Troiani10Fortunato Ciardiello11Fabiana Raffaella Rampetta12Giovanni Salzano13Giovanni Dell’Aversana Orabona14Luigi Califano15Franco Ionna16Francesco Perri17Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80128 Naples, ItalyHead and Neck Oncology Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyMedical Oncology Department, Università degli Studi di Salerno, 84084 Salerno, ItalyAbdominal Oncology Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyAnesthesiology and Pain Therapy Unit, Università degli Studi di Salerno, 84084 Salerno, ItalyHead and Neck Oncology Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyHead and Neck Oncology Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyHead and Neck Oncology Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyMaxillofacial and ENT Surgery Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyMedical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80128 Naples, ItalyMedical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80128 Naples, ItalyMedical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80128 Naples, ItalyHead and Neck Oncology Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyHead and Neck Section, Department of Neurosciences, Reproductive and Odontostomatological Science, Federico II University of Naples, 80138 Naples, ItalyHead and Neck Section, Department of Neurosciences, Reproductive and Odontostomatological Science, Federico II University of Naples, 80138 Naples, ItalyHead and Neck Section, Department of Neurosciences, Reproductive and Odontostomatological Science, Federico II University of Naples, 80138 Naples, ItalyMaxillofacial and ENT Surgery Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyHead and Neck Oncology Unit, Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale”, 80131 Naples, ItalyCheckpoint inhibitors (ICIs) have demonstrated substantial efficacy in the treatment of numerous solid tumors, including head and neck cancer. Their inclusion in the therapeutic paradigm in metastatic lines of treatment has certainly improved the outcomes of these patients. Starting from this assumption, numerous studies have been conducted on ICIs in other earlier disease settings, including studies conducted in patients in neoadjuvant settings. However, how many and which studies are truly significant? Can they lay concrete foundations for further future studies and therefore allow us to continue to have this interesting future perspective? Through a review of the existing literature, coupled with insights gleaned from clinical practice and from the main recently published studies, we aim to examine the therapeutic potential of ICIs in patients affected by head and neck cancer in a neoadjuvant treatment setting and encourage researchers to set up successful future clinical trials.https://www.mdpi.com/2227-9059/12/10/2337immunotherapyneoadjuvantcheckpoint inhibitorshead and neck squamous cell carcinomatumor mutational burden |
| spellingShingle | Alessia Zotta Maria Luisa Marciano Francesco Sabbatino Alessandro Ottaiano Marco Cascella Monica Pontone Massimo Montano Ester Calogero Francesco Longo Morena Fasano Teresa Troiani Fortunato Ciardiello Fabiana Raffaella Rampetta Giovanni Salzano Giovanni Dell’Aversana Orabona Luigi Califano Franco Ionna Francesco Perri Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach Biomedicines immunotherapy neoadjuvant checkpoint inhibitors head and neck squamous cell carcinoma tumor mutational burden |
| title | Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach |
| title_full | Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach |
| title_fullStr | Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach |
| title_full_unstemmed | Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach |
| title_short | Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach |
| title_sort | neoadjuvant immunotherapy in head and neck cancers a paradigm shift in treatment approach |
| topic | immunotherapy neoadjuvant checkpoint inhibitors head and neck squamous cell carcinoma tumor mutational burden |
| url | https://www.mdpi.com/2227-9059/12/10/2337 |
| work_keys_str_mv | AT alessiazotta neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT marialuisamarciano neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT francescosabbatino neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT alessandroottaiano neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT marcocascella neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT monicapontone neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT massimomontano neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT estercalogero neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT francescolongo neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT morenafasano neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT teresatroiani neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT fortunatociardiello neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT fabianaraffaellarampetta neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT giovannisalzano neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT giovannidellaversanaorabona neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT luigicalifano neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT francoionna neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach AT francescoperri neoadjuvantimmunotherapyinheadandneckcancersaparadigmshiftintreatmentapproach |